EGFR and non-small cell lung carcinoma: Our findings support all three progression models in NSCLC and suggest the need of vigorous attempt to identify EGFR mutation by testing all primary and metastatic tumors, regardless of the timing of metastases and the EGFR mutation status in the primary tumors, so that not to jeopardize the patients from eligible treatments.